中华眼科杂志
中華眼科雜誌
중화안과잡지
Chinese Journal of Ophthalmology
2015年
4期
314-318
,共5页
青光眼,新生血管性%滤过外科手术%血管内皮生长因子A%血管生成抑制剂%抗体,单克隆,人
青光眼,新生血管性%濾過外科手術%血管內皮生長因子A%血管生成抑製劑%抗體,單剋隆,人
청광안,신생혈관성%려과외과수술%혈관내피생장인자A%혈관생성억제제%항체,단극륭,인
Glaucoma,neovascular%Filtering surgery%Vascular endothelial growth factor A%Angiogenesis inhibitors%Antibodies,monoclonal,humanized
新生血管性青光眼(NVG)是一种由多种疾病导致视网膜缺血缺氧而发生的继发性青光眼,研究发现其病因与VEGF有关.目前,抗VEGF药物作为治疗NVG的手段之一,已成为现阶段青光眼研究领域的热点,为提高NVG疗效开辟了新的途径.本文就有关NVG病理生理基础与临床过程,包括Bevacizumab、Ranibizumab、Pegaptanib及Aflibercept在内的4种抗VEGF药物的基础研究,抗VEGF药物在NVG及滤过手术抗瘢痕治疗中应用的国内外研究进展进行综述,以期为临床治疗NVG、提高手术成功率提供参考.
新生血管性青光眼(NVG)是一種由多種疾病導緻視網膜缺血缺氧而髮生的繼髮性青光眼,研究髮現其病因與VEGF有關.目前,抗VEGF藥物作為治療NVG的手段之一,已成為現階段青光眼研究領域的熱點,為提高NVG療效開闢瞭新的途徑.本文就有關NVG病理生理基礎與臨床過程,包括Bevacizumab、Ranibizumab、Pegaptanib及Aflibercept在內的4種抗VEGF藥物的基礎研究,抗VEGF藥物在NVG及濾過手術抗瘢痕治療中應用的國內外研究進展進行綜述,以期為臨床治療NVG、提高手術成功率提供參攷.
신생혈관성청광안(NVG)시일충유다충질병도치시망막결혈결양이발생적계발성청광안,연구발현기병인여VEGF유관.목전,항VEGF약물작위치료NVG적수단지일,이성위현계단청광안연구영역적열점,위제고NVG료효개벽료신적도경.본문취유관NVG병리생리기출여림상과정,포괄Bevacizumab、Ranibizumab、Pegaptanib급Aflibercept재내적4충항VEGF약물적기출연구,항VEGF약물재NVG급려과수술항반흔치료중응용적국내외연구진전진행종술,이기위림상치료NVG、제고수술성공솔제공삼고.
Neovascular glaucoma (NVG) is a group of secondary glaucoma which led by a variety of diseases that have anoxia or ischemia to the retina.Some studies have found that the etiology was related to the vascular endothelial growth factor(VEGF).At present,anti-VEGF as a treatment method to NVG,has become an important advancc in the field of glaucoma research,which established a new way to improve the prognosis.This review mainly focused on the pathophysiologic basis and clinical research of NVG,fundamental research and applications about four kinds of anti-VEGF agents (Bevacizumab,Ranibizumab,Pegaptanib and Aflibercept) and application of treatment of NVG and anti-scarring in filtering surgery.The review also provided references for the clinical treatment of NVG and improving the success rate of operation.
